Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In lab studies with mice, the therapy restored resident immune cells of the central nervous system, which could indicate…
News
News
ALS Therapy Radicava Seen to Uphold Benefits Over Nearly a Year in Extension Trial, Says MT Pharma
Data from the open-label extension trial of Radicava (edaravone) in patients with amyotrophic lateral sclerosis (ALS) demonstrated that the treatment continued to provide benefits after 48 weeks of treatment. These findings — presented by researchers from MT Pharma America at the May 18-20 European Network for the Cure…
News
Masitinib Phase 3 Trial Data Show Slowed Amyotrophic Lateral Sclerosis Progression, AB Science Says
French biotech company AB Science presented the results of the Phase 3 clinical trial for its lead compound masitinib, which showed effectiveness in improving the functioning of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The randomized, double-blind clinical trial (NCT02588677) compared the efficacy and…
Mutations in the UBQLN4 gene may contribute to the development of amyotrophic lateral sclerosis (ALS), according to recent research. The study, “A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis,” was published in the journal eLife. Over the years, researchers have identified numerous genes linked to ALS, but the list…
BrainStorm Cell Therapeutics has begun training the cell manufacturing team at City of Hope’s Center for Biomedicine and Genetics to produce NurOwn adult stem cells for a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Los Angeles-based City of Hope will be the clinical…
AB Science will suspend its ongoing masitinib studies in France in patients with cutaneous mastocytosis. However, its studies in patients with amyotrophic lateral sclerosis (ALS) can continue. The pharmaceutical company said it received notice from the French medicines agency Agence Nationale de la Sécurité des Médicaments,…
A gene therapy aimed at strengthening the connection between motor neurons and muscle prevented nerve degeneration and increased the life span of mice with amyotrophic lateral sclerosis (ALS), a study showed. Since researchers believe that neurodegeneration in ALS starts at the junction between nerves and muscle, the findings suggest that…
More than 260 Dutch Bros. Coffee locations in seven American states have raised $970,037 for the Muscular Dystrophy Association‘s patient-services and research programs, which include ALS, the disease that claimed Dutch Bros. co-founder Dane Boersma. To honor Boersma, the company calls its annual fund-raiser Drink One for Dane Day. In addition…
The 6th annual Roll on Capitol Hill, organized by the United Spinal Association, will advocate for greater access to properly configured and medically-necessary wheelchairs for people with spinal cord injuries and disorders (SCI/D). The event will take place from June 11-14 in Washington, D.C. Andrea Dalzell, Ms. Wheelchair New…
Researchers have developed an antibody, called armanezumab, which specifically targets defective tau protein. The molecule has potential for the treatment of amyotrophic lateral sclerosis (ALS), among other diseases. According to results of the study “Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency,”…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.